Back to results
US 2026/0274991 A1Published application
Dual inhibitor trypsin antibodies and uses thereof
AssigneeTriveni Bio, Inc.
InventorsJennifer L. Dovey, Allan Capili, Brantley Herrin, Jason Hon, Ye Tang, Sonya Entova, Todd Borland, Eva Asp, Jia Li, Libin Lui, Leonard Zon, Bradley Lunde
Life of this patent
Estimating the term…
Abstract
Aspects of the application provide dual inhibitor anti-trypsin 1/trypsin 2 antibodies and methods of using the same for treating pancreatitis.
Claims21
A dual inhibitor antibody that specifically binds to trypsin 1 and trypsin 2, the dual inhibitor antibody comprising
- (a) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO:
- 57, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain (VL) having the amino acid sequence of SEQ ID NO:
- 58;
- (b) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 59, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 60;
- (c) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 61, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 62;
- (d) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 63, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 64;
- (e) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 65, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 66;
- (f) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 67, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 68;
- (g) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 69, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 70;
- (h) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 71, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 70;
- (i) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 72, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 73;
- (j) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 74, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 73;
- (k) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 75, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 73;
- (l) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 76, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 73;
- (m) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 77, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 78;
- (n) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 79, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 80;
- (o) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 81, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 82;
- (p) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 83, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 70;
- or
- (q) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 84, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO:
- 70.
49 more elements
A dual inhibitor antibody comprising
- (i) a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and/or LC CDR3 of any one of the antibodies listed in Table 1a and Table 1b;
- or
- (ii) a VH and/or a VL of any one of the antibodies listed in Table 1a.
A method of treating pancreatitis, the method comprising administering to a subject in need thereof an effective amount of at least one antibody that specifically binds to trypsin 1 and/or trypsin 2.
A polypeptide comprising a sequence as set forth in SEQ ID NO:
- 103 or a fragment thereof suitable for generating an antibody that specifically binds to and inhibits protease activity of trypsin 1, optionally wherein the polypeptide comprises a detectable tag, such as a His-tag.
A polypeptide comprising a sequence as set forth in SEQ ID NO:
- 104 or a fragment thereof suitable for generating an antibody that specifically binds to and inhibits protease activity of trypsin 2, optionally wherein the polypeptide comprises a detectable tag, such as a His-tag.
Dependencies are inferred from the claim text.